Please login to the form below

Not currently logged in
Email:
Password:

Mesoblast

This page shows the latest Mesoblast news and features for those working in and with pharma, biotech and healthcare.

Stem cell therapy promising for rheumatoid arthritis

Stem cell therapy promising for rheumatoid arthritis

Stem cell therapy promising for rheumatoid arthritis. Mesoblast’ s phase II trial sees "impressive efficacy" in refractory patients. ... Mesoblast's MPCs are off-the-shelf, allogeneic stem cell therapies that do not rely on harvesting cells from

Latest news

More from news
Approximately 2 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • Heart failure therapy embarks on a new era Heart failure therapy embarks on a new era

    trial; Mesoblast/Teva with allogenic mesenchymal stem cell therapy Neofuse; and Celyad's C-Cure, based on autologous cardiac stem cells.

  • Pharma deals in April 2015 Pharma deals in April 2015

    As mentioned above, Celgene had an exceptionally busy month announcing deals with Quanticel Pharmaceuticals, AZ, Agios Pharmaceuticals, Mesoblast and Northern Biologics. ... Celgene's other deals are with Agios Pharmaceuticals, Mesoblast and AZ. With

  • Medius Deal Watch table for April 2015 Medius Deal Watch table for April 2015

    49. Mesoblast / Celgene. Minority investment and option to license. stem-cell product candidates for conditions including inflammatory bowel disease and certain oncological indications.

  • Deal Watch table for October 2013 Deal Watch table for October 2013

    Commercialisation. Oralair, grass allergy sublingual tablet (pre-registration). 120. Osiris Therapeutics / Mesoblast .

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

  • Weekly industry appointments Weekly industry appointments

    Weekly industry appointments. GSK’s CSO cell and gene therapy heads for the exit, Gelesis adds to company, Abcam appoints Peter Allen and Joseph Swedish joins Mesoblast’s board. ... Joseph Swedish joins Mesoblast’s board. Cell-based medicines group

More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hanson Zandi

Hanson Zandi is a Creative and Digital Healthcare Agency. We combine 30 years’ experience with the enthusiasm of a start-up...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics